Key result
Diabetic cardiomyopathy is driven by mechanisms such as lipotoxicity and oxidative stress, with SGLT-2 inhibitors emerging as a preferred therapy to improve cardiovascular outcomes.
Why the study?
Diabetes mellitus and heart failure have a bidirectional relationship, and emerging targeted therapies for diabetic cardiomyopathy require further evaluation.
This narrative review provides a comprehensive overview of the pathophysiological mechanisms underlying diabetic cardiomyopathy and highlights the emerging role of SGLT2 inhibitors and targeted therapies in its management.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in diabetic cardiomyopathy; leaves open confirmation of SGLT-2 inhibitor benefits in dedicated RCTs.
Diabetes mellitus and heart failure have a bidirectional relationship and can affect one another. Ventricular dysfunction that occurs in the absence of coronary atherosclerosis and hypertension in patients with diabetes mellitus is termed diabetic cardiomyopathy. Lipotoxicity, increased oxidative stress and mitochondrial dysfunction are a few of the mechanisms implicated in diabetic cardiomyopathy. Patients with diabetes mellitus undergo cardiac structural changes leading to heart failure. The novel glucose-lowering medication that is now preferred for diabetic patients with heart failure is the SGLT-2 (sodium-glucose cotransporter 2) inhibitor. Emerging targeted therapies are showing beneficial effects but require further evaluation. We review the literature describing the pathophysiology of diabetic cardiomyopathy, cardiac structural changes, along with the novel glucose-lowering therapies and targeted therapies for diabetic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Laksono et al. (2022) conducted a review in Diabetic cardiomyopathy. SGLT-2 inhibitors and novel targeted therapies was evaluated. Diabetic cardiomyopathy is driven by mechanisms such as lipotoxicity and oxidative stress, with SGLT-2 inhibitors emerging as a preferred therapy to improve cardiovascular outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: